Can a cardiologist interpret Doppler measurements of diastolic filling, including an E/A (E-to-A wave ratio) ratio of 0.69, MV (mitral valve) E' tissue velocity lateral of 9.8 cm/s, MV E' tissue velocity medial of 6.5 cm/s, and an E wave deceleration time of 236 msec, in a patient with potential impaired renal function, indicated by elevated Cystatin C levels, and likely underlying cardiovascular risk factors such as hypertension or diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Interpretation of Diastolic Doppler Measurements

Yes, a cardiologist can definitively interpret these measurements, which indicate Grade I diastolic dysfunction (impaired relaxation pattern) with normal left ventricular filling pressures. 1

Analysis of Your Specific Values

E/A Ratio of 0.69

  • This confirms Grade I diastolic dysfunction, falling below the diagnostic threshold of ≤0.8 that defines impaired relaxation. 1, 2
  • The normal range for E/A ratio varies by age: 0.73-2.33 (ages 21-40), 0.78-1.78 (ages 41-60), and 0.6-1.32 (>60 years). 1
  • Your value indicates delayed left ventricular relaxation, the primary abnormality in early diastolic dysfunction, not elevated filling pressures. 2

Tissue Doppler E' Velocities

  • Lateral e' of 9.8 cm/s is borderline reduced (normal ≥10 cm/s for ages <60, or ≥5.9 cm/s for ages >60). 1, 3, 4
  • Septal e' of 6.5 cm/s is reduced (normal ≥7 cm/s), indicating impaired myocardial relaxation. 1, 3, 4
  • The average e' is approximately 8.2 cm/s, which is mildly reduced and consistent with early diastolic dysfunction. 1, 3

E/e' Ratio Calculation

  • Using the average e' of 8.2 cm/s, the E/e' ratio would be <8, definitively indicating normal left ventricular filling pressures. 1, 4
  • For septal E/e', values <8 are normal and >15 are elevated, with 8-15 being indeterminate. 1
  • This is critical: despite having diastolic dysfunction, your filling pressures remain normal. 2, 4

E Wave Deceleration Time of 236 msec

  • This is prolonged (normal range 138-194 msec for ages 21-40,143-219 msec for ages 41-60,142-258 msec for >60 years). 1
  • Prolonged deceleration time confirms the impaired relaxation pattern and excludes restrictive physiology (which would show DT <160 msec). 1

Clinical Significance in Context of Cardiovascular Risk

Hypertension and Diabetes Connection

  • Delayed relaxation occurs characteristically in uncomplicated systemic arterial hypertension, making this pattern expected in hypertensive patients. 1
  • The elevated cystatin C mentioned suggests early vascular and renal damage, which correlates with cardiovascular risk factors. 5, 6
  • Cystatin C elevation is independently associated with diabetes, hypertension, and decreased glomerular filtration. 6, 7

Prognostic Implications

  • Normal in-treatment transmitral flow pattern indicates low risk for heart failure (HR 0.22,95% CI 0.05-0.98). 1
  • However, Grade I diastolic dysfunction requires monitoring as it can progress to higher grades with elevated filling pressures. 2
  • The combination of reduced e' velocities (particularly septal e' <7 cm/s) warrants attention, though values are not severely reduced (<5 cm/s would indicate advanced dysfunction). 3

Critical Pitfalls to Avoid

Pseudonormalization Risk

  • The E/A ratio of 0.69 is too low to represent pseudonormalization (which occurs with E/A 0.8-2.0 and elevated E/e' >14). 2
  • In patients with reduced ejection fraction, pseudonormal patterns can masquerade as normal, but your low E/A ratio excludes this. 2
  • Valsalva maneuver is unnecessary here given the clearly abnormal E/A ratio. 1, 2

E/e' Ratio Limitations

  • Always average septal and lateral e' values for optimal global diastolic function assessment, particularly important with regional dysfunction. 1, 4
  • E/e' has limited accuracy with mitral annular calcification, mitral valve disease, pericardial disease, or atrial fibrillation. 4
  • The correlation between E/e' and invasively measured filling pressures is only modest (r=0.56). 4

Recommended Clinical Approach

Immediate Assessment

  • Confirm left atrial volume index (normal <34 mL/m²) to exclude chronically elevated pressures. 2
  • Measure tricuspid regurgitation velocity (normal <2.8 m/sec) to further confirm absence of elevated pressures. 1, 2
  • Assess left ventricular mass and geometry to quantify hypertensive heart disease severity. 1

Management Strategy

  • Aggressively control hypertension with ACE inhibitors or ARBs to improve ventricular relaxation and promote regression of hypertrophy. 2
  • Use beta-blockers to lower heart rate and increase diastolic filling period, particularly beneficial with concomitant coronary disease. 2
  • Manage contributing factors including obesity, diabetes (given elevated cystatin C), and optimize glycemic control. 2, 6

Surveillance Plan

  • Regular echocardiographic monitoring to detect progression to Grade II (pseudonormal pattern with E/A 0.8-2.0 and E/e' 8-14) or Grade III (restrictive pattern with E/A ≥2.0 and E/e' >14). 2
  • Watch for left atrial dilatation, which is a marker of longstanding increased LA pressure in hypertensive heart disease. 1
  • Consider diastolic stress testing if symptoms develop despite normal resting parameters. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diastolic Dysfunction Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tissue Doppler Imaging in Cardiac Function Assessment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

E/e' Ratio in Clinical Practice

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Serum cystatin C and microalbuminuria in the detection of vascular and renal damage in early stages.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011

Research

[Cystatin C and cardiovascular risk in the general population].

Revista espanola de cardiologia, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.